TSX · EPRX.TO
Eupraxia Pharmaceuticals Inc.
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
Loading market information…
OTC · IMUC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
EOM Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow EOM Pharmaceuticals Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as well as in Phase ½ a clinical trial to treat infectious diseases, such as COVID-19. It also develops EOM 147, an investigational broad-spectrum aminosterol with an intracellular mechanism that has completed Phase 2 clinical trial for the treatment of age-related macular degeneration, diabetic retinopathy, and macular edema due to retinal vain occlusion. EOM Pharmaceuticals Holdings, Inc. was founded in 2020 and is headquartered in Montvale, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
$3.04+$0.28 (+10.14%)
Eledon Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.91% below the high.
$1.42$0.00 (0.0%)
Equillium, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.89% below the high.
$3.90-$0.13 (-3.23%)
Clene Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.11% below the high.
$0.66-$0.02 (-3.58%)
Aldeyra The’s quoted price sits in the lower half of its reported 52-week range, 88.89% below the high.
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
$1.50-$0.10 (-6.25%)
CEL-SCI Corporation’s quoted price sits in the lower half of its reported 52-week range, 80.77% below the high.
$2.70+$0.14 (+5.47%)
Edesa Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.71% below the high.
